Roles of lncRNA in the diagnosis and prognosis of triple-negative breast cancer.
- Author:
Qiuhui YANG
1
;
Yeqin FU
1
;
Jiaxuan WANG
2
;
Hongjian YANG
1
;
Xiping ZHANG
3
Author Information
- Publication Type:Journal Article
- Keywords: Chemotherapy resistance; Diagnosis; Long non-coding RNA (lncRNA); Prognosis; Triple-negative breast cancer (TNBC)
- MeSH: Humans; Female; Triple Negative Breast Neoplasms/genetics*; RNA, Long Noncoding/genetics*; Biomarkers, Tumor/genetics*; Gene Expression Regulation, Neoplastic
- From: Journal of Zhejiang University. Science. B 2023;24(12):1123-1140
- CountryChina
- Language:English
- Abstract: Breast cancer is a malignant tumor that seriously endangers women's lives. The prognosis of breast cancer patients differs among molecular types. Compared with other subtypes, triple-negative breast cancer (TNBC) has been a research hotspot in recent years because of its high degree of malignancy, strong invasiveness, rapid progression, easy of recurrence, distant metastasis, poor prognosis, and high mortality. Many studies have found that long non-coding RNA (lncRNA) plays an important role in the occurrence, proliferation, migration, recurrence, chemotherapy resistance, and other characteristics of TNBC. Some lncRNAs are expected to become biomarkers in the diagnosis and prognosis of TNBC, and even new targets for its treatment. Based on a PubMed literature search, this review summarizes the progress in research on lncRNAs in TNBC and discusses their roles in TNBC diagnosis, prognosis, and chemotherapy with the hope of providing help for future research.
